A randomized phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II non-small-cell lung cancer
We investigated the feasibility of cisplatin or carboplatin combined with pemetrexed as adjuvant treatment in patients with completely resected Stage IB/II Non-Small-Cell Lung Cancer (NSCLC). Patients in this multicenter, open-label, parallel-group, non-comparative Phase 2 study were randomized (1:1...
Gespeichert in:
| 1. Verfasser: | |
|---|---|
| Dokumenttyp: | Article (Journal) |
| Sprache: | Englisch |
| Veröffentlicht: |
December 2015
|
| In: |
Lung cancer
Year: 2015, Jahrgang: 90, Heft: 3, Pages: 397-404 |
| ISSN: | 1872-8332 |
| DOI: | 10.1016/j.lungcan.2015.11.007 |
| Online-Zugang: | Verlag, Volltext: http://dx.doi.org/10.1016/j.lungcan.2015.11.007 Verlag, Volltext: http://www.sciencedirect.com/science/article/pii/S0169500215301021 
|
| Verfasserangaben: | Gerald Schmid-Bindert, Walburga Engel-Riedel, Martin Reck, Wolfgang Schuette, Jan Stöhlmacher, Jürgen R. Fischer, Julien Mazières, Christos Chouaid, Martin Wolf, Nuria Vinolas, Victoria Soldatenkova, Veronique Ripoche, Tuan Nguyen, Carla Visseren-Grul |
MARC
| LEADER | 00000caa a2200000 c 4500 | ||
|---|---|---|---|
| 001 | 1564811697 | ||
| 003 | DE-627 | ||
| 005 | 20230427142101.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 171026s2015 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.lungcan.2015.11.007 |2 doi | |
| 035 | |a (DE-627)1564811697 | ||
| 035 | |a (DE-576)494811692 | ||
| 035 | |a (DE-599)BSZ494811692 | ||
| 035 | |a (OCoLC)1340981267 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 084 | |a 33 |2 sdnb | ||
| 100 | 1 | |a Schmid-Bindert, Gerald |d 1969- |e VerfasserIn |0 (DE-588)121300129 |0 (DE-627)081214170 |0 (DE-576)292636024 |4 aut | |
| 245 | 1 | 2 | |a A randomized phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II non-small-cell lung cancer |c Gerald Schmid-Bindert, Walburga Engel-Riedel, Martin Reck, Wolfgang Schuette, Jan Stöhlmacher, Jürgen R. Fischer, Julien Mazières, Christos Chouaid, Martin Wolf, Nuria Vinolas, Victoria Soldatenkova, Veronique Ripoche, Tuan Nguyen, Carla Visseren-Grul |
| 264 | 1 | |c December 2015 | |
| 300 | |a 8 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 26.10.2017 | ||
| 520 | |a We investigated the feasibility of cisplatin or carboplatin combined with pemetrexed as adjuvant treatment in patients with completely resected Stage IB/II Non-Small-Cell Lung Cancer (NSCLC). Patients in this multicenter, open-label, parallel-group, non-comparative Phase 2 study were randomized (1:1) to pemetrexed (500mg/m2) with either cisplatin (75mg/m2) or carboplatin (AUC5) for 4 cycles of 21 days. The primary endpoint was treatment feasibility (defined as 4 cycles completed with no cycle delay >42 days and ≤2 dose reductions, with a median relative dose intensity (RDI) ≥95% [overall]; and no Grade ≥3 toxicities at the follow-up visit 30 days after last drug administration). Secondary objectives included overall survival (OS) and safety. We randomized 122 patients and treated 118. 71.9% (46/64) of patients in pemetrexed+cisplatin and 88.9% (48/54) in pemetrexed+carboplatin completed 4 cycles (median RDI >97% for all compounds). Neither treatment met the pre-defined feasibility level >60% of patients: 59.4% (95% confidence interval [CI]: 46.4;71.5) pemetrexed+cisplatin; 50.0% (95%CI: 36.1;63.9) in pemetrexed+carboplatin. In a post-hoc analysis considering only safety, both regimens were feasible with 81.3% (95%CI: 69.5;89.9) in pemetrexed+cisplatin and 90.7% (95%CI: 79.7;96.9) in pemetrexed+carboplatin. OS rates for both groups were 82-83% after 3 years and 80-83% after 5 years. Treatment-related Grade ≥3 adverse events (mostly hematological) were experienced by approximately 30% of patients in each group. Although the study did not meet the primary objective, both treatment groups demonstrated good safety-related feasibility and tolerability as adjuvant treatment in patients with completely resected Stage IB/II NSCLC. | ||
| 650 | 4 | |a Adjuvant treatment | |
| 650 | 4 | |a Feasibility | |
| 650 | 4 | |a NSCLC | |
| 650 | 4 | |a Pemetrexed | |
| 773 | 0 | 8 | |i Enthalten in |t Lung cancer |d Amsterdam [u.a.] : Elsevier, 1985 |g 90(2015), 3, Seite 397-404 |h Online-Ressource |w (DE-627)320649733 |w (DE-600)2025812-4 |w (DE-576)264627539 |x 1872-8332 |7 nnas |a A randomized phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II non-small-cell lung cancer |
| 773 | 1 | 8 | |g volume:90 |g year:2015 |g number:3 |g pages:397-404 |g extent:8 |a A randomized phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II non-small-cell lung cancer |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.lungcan.2015.11.007 |x Verlag |x Resolving-System |3 Volltext |
| 856 | 4 | 0 | |u http://www.sciencedirect.com/science/article/pii/S0169500215301021 |x Verlag |3 Volltext |
| 951 | |a AR | ||
| 992 | |a 20171026 | ||
| 993 | |a Article | ||
| 994 | |a 2015 | ||
| 998 | |g 121300129 |a Schmid-Bindert, Gerald |m 121300129:Schmid-Bindert, Gerald |d 60000 |d 61800 |e 60000PS121300129 |e 61800PS121300129 |k 0/60000/ |k 1/60000/61800/ |p 1 |x j | ||
| 999 | |a KXP-PPN1564811697 |e 2986113346 | ||
| BIB | |a Y | ||
| SER | |a journal | ||
| JSO | |a {"title":[{"title_sort":"randomized phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II non-small-cell lung cancer","title":"A randomized phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II non-small-cell lung cancer"}],"note":["Gesehen am 26.10.2017"],"language":["eng"],"type":{"bibl":"article-journal","media":"Online-Ressource"},"relHost":[{"physDesc":[{"extent":"Online-Ressource"}],"recId":"320649733","disp":"A randomized phase 2 study of pemetrexed in combination with cisplatin or carboplatin as adjuvant chemotherapy in patients with completely resected stage IB or II non-small-cell lung cancerLung cancer","origin":[{"dateIssuedDisp":"1985-","dateIssuedKey":"1985","publisherPlace":"Amsterdam [u.a.]","publisher":"Elsevier"}],"pubHistory":["1.1985 -"],"language":["eng"],"type":{"bibl":"periodical","media":"Online-Ressource"},"note":["Gesehen am 20.02.20"],"id":{"zdb":["2025812-4"],"eki":["320649733"],"issn":["1872-8332"]},"title":[{"title":"Lung cancer","title_sort":"Lung cancer","subtitle":"journal of the International Association for the Study of Lung Cancer"}],"part":{"volume":"90","year":"2015","extent":"8","text":"90(2015), 3, Seite 397-404","issue":"3","pages":"397-404"}}],"person":[{"given":"Gerald","role":"aut","family":"Schmid-Bindert","display":"Schmid-Bindert, Gerald"}],"origin":[{"dateIssuedDisp":"December 2015","dateIssuedKey":"2015"}],"recId":"1564811697","physDesc":[{"extent":"8 S."}],"id":{"eki":["1564811697"],"doi":["10.1016/j.lungcan.2015.11.007"]},"name":{"displayForm":["Gerald Schmid-Bindert, Walburga Engel-Riedel, Martin Reck, Wolfgang Schuette, Jan Stöhlmacher, Jürgen R. Fischer, Julien Mazières, Christos Chouaid, Martin Wolf, Nuria Vinolas, Victoria Soldatenkova, Veronique Ripoche, Tuan Nguyen, Carla Visseren-Grul"]}} | ||
| SRT | |a SCHMIDBINDRANDOMIZED2015 | ||